This announcement is a separate document:
GlaxoSmithKline | 6-K: Viiv Healthcare Announces Interim Data at Croi Indicating Superior Efficacy of Long-Acting Injectable Hiv Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living with Hiv Who Have Adheren
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.